Advance in studies on traditional Chinese medicines to treat infection with the hepatitis B virus and hepatitis C virus

Xia, Jufeng; Inagaki, Yoshiaki; Song, Peipei; Sawakami, Tatsuo; Kokudo, Norihiro; Hasegawa, Kiyoshi; Tang, Wei

doi:10.5582/bst.2016.01110

Cited by 18 publications

(12 citation statements)

References 67 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to TCM theory, these phenomena are primarily patterned as hepatobiliary damp-heat. Among the top ten herbs and formulas, XCHT, Radix et Rhizoma Rhei , Radix astragali , and Scutellaria radix exert anti-HBV activity, while XCHT has exhibited anti-HCV activity in a phase II clinical trial [29].…”

Section: Discussionmentioning

confidence: 99%

Chinese Herbal Medicine Ameliorated the Development of Chronic Kidney Disease in Patients with Chronic Hepatitis C: A Retrospective Population-Based Cohort Study

Chang

Lin

et al. 2019

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a serious complication affecting patients with chronic hepatitis. The effectiveness of CHM for the prevention of CKD in hepatitis patients remains unclear. Therefore, we conducted a retrospective cohort study to investigate the effectiveness of CHM in preventing the development of CKD in hepatitis patients. From a subdataset of the Taiwan National Health Insurance Research Database (NHIRD), we included 19,409 patients newly diagnosed with hepatitis B and hepatitis C between the years 2000 and 2010. After exclusion criteria and 1 : 1 propensity score matching process, we compared demographic factors, comorbidities, and correlated drugs between the CHM and non-CHM cohorts. Statistical analysis was applied to evaluate the differences in characteristic distributions and to compare the cumulative incidence of CKD between the CHM and non-CHM cohorts. This study showed that the patients suffering from hepatitis C with CHM treatment more than 90 days as an adjuvant therapy combined with western medical treatment modalities exhibited a decreased risk of developing CKD (hazard ratio (HR) = 0.40, 95% confidence interval (CI) = 0.21–0.76, p value <0.01). The Kaplan–Meier curve revealed a lower cumulative incidence rate of CKD (p value = 0.004) for the CHM cohort. For further reference, we herein offer the ten most frequently prescribed single herbs and herbal formulas; as such, Salviae miltiorrhizae and Jia-Wei-Xiao-Yao-San were the most commonly prescribed single herb and formula, respectively. This nationwide retrospective cohort study provides evidence that CHM is an effective adjuvant treatment to decrease the risk of developing CKD in hepatitis C patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Chinese Herbal Medicine Ameliorated the Development of Chronic Kidney Disease in Patients with Chronic Hepatitis C: A Retrospective Population-Based Cohort Study

Chang

Lin

et al. 2019

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Antiviral treatment has progressed in previous years, however, its application remains limited due to its high cost, prolonged therapy, frequent relapse following therapy cessation, and various side effects ( 25 ). As investigations of traditional Chinese medicine have progressed, the identification of drugs and therapies from TCMs with high efficiency, low toxicity and anti-HBV effects has been a focus of interest in medicine ( 26 ).…”

Section: Discussionmentioning

confidence: 99%

Effect of modified Xiaochaihu decoction-containing serum on HepG2.2.15 cells via the JAK2/STAT3 signaling pathway

Chen

Wang

Shichuan

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

The present study aimed to investigate the possible mechanisms underlying the effect of modified Xiaochaihu decoction (mXCHD) in the treatment of chronic hepatitis B (CHB). Patients with CHB, in addition to liver stagnation and spleen deficiency syndrome were randomly assigned to receive either Chinese (mXCHD) or western (entecavir) treatment, with 30 cases in each group. Serum was collected following treatment with mXCHD or entecavir for 7 days. A healthy group of 30 individuals was also included. HepG2.2.15 cells were cultured in vitro and randomly divided into four groups: Healthy; entecavir-treated; 10% mXCHD-treated; and 20% mXCHD-treated. The HepG2.2.15 cells in the four groups were treated with either serum from the healthy volunteers, entecavir-containing serum, or mXCHD-containing serum at different concentrations (10 or 20%, respectively). Following treatment with the corresponding serum, cell proliferation was examined using an MTT assay, and the expression of hepatitis B surface antigen (HBsAg) in the cell supernatant was detected using an enzyme-linked immunosorbent assay. The mRNA and protein expression levels of Janus kinase (JAK)2 and signal transducer and activator of transcription (STAT)3 were measured using reverse transcription-quantitative polymerase chain reaction and western blot analyses, respectively. The results indicated that the most effective treatment for the promotion of HepG2.2.15 cell proliferation was a 20% concentration of mXCHD serum. The expression of HBsAg was significantly decreased in the groups treated with 10 and 20% mXCHD 48 h following intervention (P<0.01). The mRNA and protein expression levels of STAT3 in the 20% mXCHD serum group were significantly increased, compared with those in the healthy group (P<0.01 and P<0.05, respectively), whereas no significant difference was observed in the expression of JAK2 among the four groups. These results indicated that mXCHD suppressed the hepatitis B virus, and treatment of the cells with mXCHD-containing serum promoted HepG2.2.15 cell proliferation via modulating the expression of STAT3, which may contribute to the clinical efficacy of mXCHD against CHB.

show abstract

“…), Gardenia jasminoides Elli, Scutellaria baicalensis Georgi, and Lonicera japonica Thunb. All of these herbs are widely used in clinical practice for the treatment of hepatitis [9][10][11][12] .…”

mentioning

confidence: 99%

A bioinformatics investigation into molecular mechanism of Yinzhihuang granules for treating hepatitis B by network pharmacology and molecular docking verification

Zhang

Liu

Zhou

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Yinzhihuang granules (YZHG) is a patented Chinese medicine for the treatment of hepatitis B. This study aimed to investigate the intrinsic mechanisms of YZHG in the treatment of hepatitis B and to provide new evidence and insights for its clinical application. The chemical compounds of YZHG were searched in the CNKI and PUBMED databases, and their putative targets were then predicted through a search of the SuperPred and Swiss Target Prediction databases. In addition, the targets of hepatitis B were obtained from TTD, PharmGKB and DisGeNET. The abovementioned data were visualized using Cytoscape 3.7.1, and network construction identified a total of 13 potential targets of YZHG in the treatment of hepatitis B. Molecular docking verification showed that CDK6, CDK2, TP53 and BRCA1 might be strongly correlated with hepatitis B treatment. Furthermore, GO and KEGG analyses indicated that the treatment of hepatitis B by YZHG might be related to positive regulation of transcription, positive regulation of gene expression, the hepatitis B pathway and the viral carcinogenesis pathway. Network pharmacology intuitively shows the multicomponent, multitarget and multichannel pharmacological effects of YZHG in the treatment of hepatitis B and provides a scientific basis for its mechanism of action. The cause of hepatitis B is hepatitis B virus (HBV), which is a double-stranded, circular, incompletely closed DNA virus 1-3. Antiviral therapy involving pegylated interferon or nucleoside analogs (lamivudine, adefovir, entecavir, tenofovir disoproxil, or tenofovir alafenamide) is currently provided clinically to patients with hepatitis B to inhibit HBV DNA replication and improve liver inflammation and fibrosis 4,5 , but this treatment protocol requires patients to be treated indefinitely and has a relatively low cure rate. Researchers are constantly searching for more effective drugs. In addition, the long-term use of nucleos(t)ide analogs (NAs) might lead to drug resistance and renal damage and cannot reverse liver fibrosis. Therefore, an increasing number of people have begun to focus on Chinese herbal medicines and seek safer and more cost-effective supplementary drugs for hepatitis B 6-8. Chinese herbal medicines have a long history of use in China. In recent years, researchers have continuously found effective pharmaceutical ingredients and targets for the treatment of diseases from Chinese herbal medicines. These results show that Chinese herbal medicines constitute extremely rich resources, and the discovery of new medicine sources from Chinese herbal medicine is becoming a major method of drug development. Yinzhihuang granules (YZHG) can clear away heat and toxic materials, promote diuresis and eliminate jaundice. The prescription is composed of "Yinchenhao Decoction" (Han, Zhongjing Zhang, "Treatise on Febrile Diseases") and "Huanglianjiedu Decoction" (Tang, Tao Wang, "Essential Secrets from Outside the Metropolis"). The YZHG

show abstract

Advance in studies on traditional Chinese medicines to treat infection with the hepatitis B virus and hepatitis C virus

Cited by 18 publications

References 67 publications

Chinese Herbal Medicine Ameliorated the Development of Chronic Kidney Disease in Patients with Chronic Hepatitis C: A Retrospective Population-Based Cohort Study

Chinese Herbal Medicine Ameliorated the Development of Chronic Kidney Disease in Patients with Chronic Hepatitis C: A Retrospective Population-Based Cohort Study

Effect of modified Xiaochaihu decoction-containing serum on HepG2.2.15 cells via the JAK2/STAT3 signaling pathway

A bioinformatics investigation into molecular mechanism of Yinzhihuang granules for treating hepatitis B by network pharmacology and molecular docking verification

Contact Info

Product

Resources

About